Liza Moore, MD
Dermatology · Mc Lean, VANPI 1730405010
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $100,732 of the $149,099 with a category attached, or 67.6%. 44 manufacturers reported payments, led by AbbVie at 40.5% of the total. Reporting peaked in 2019 at $60,951 and has fallen 88.8% since, to $6,828 in 2025. Among dermatology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 891 payments — averaging $167.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60K
- Bristol Myers Squibb$37K
- Galderma Laboratories, L.p.$19K
- Amgen$11K
- Pfizer$10K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $10K from 38 others
Across 6 payments — averaging $1666.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Consulting fees$17,77612%
- Speaking & faculty fees$100,73268%
- Travel & lodging$9,7017%
- Food & beverage$20,52114%
- Education$3360%
- Gifts$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,099 in reported general payments places this provider in the 95th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desonide | 13 | $1,525 |
| Ketoconazole | 15 | $1,380 |
| Clobetasol Propionate | 14 | $560 |
| Ciclopirox | 12 | $500 |
| CiclopiroxCiclopirox Olamine | 19 | $401 |
| Mometasone Furoate | 21 | $370 |
| Mupirocin | 21 | $184 |
| Triamcinolone Acetonide | 14 | $167 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Mc Lean
- Lily TalakoubMc Lean$18K
- Naiem IssaVienna$2M
- Saurabh SinghFairfax$1.7M
- Diego DasilvaVirginia Beach$1.1M
- Vishal PatelLeesburg$719K
- Cyndi Torosky TommasoVirginia Beach$717K
- Daniel HurdBlacksburg$545K
- Jonathan SchreiberNorfolk$330K
- Robert BaerSuffolk$303K
- David PariserNorfolk$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.